← 返回前沿论文

成人肿瘤患者自体造血干细胞移植后 NK 细胞亚群动态变化

英文原题:Dynamics of NK cell subsets following autologous hematopoietic stem cell transplantation in adult oncologic patients.

PubMed 2025/10/07(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

研究概要

我们的发现共同为 autoHSCT 后免疫重建过程中的 NK 细胞动态变化提供了有价值的见解,并可能为改善患者管理的策略提供启示。

中文摘要

自体造血干细胞移植(autoHSCT)后的早期免疫重建与多种癌症患者结局改善相关。自然杀伤(NK)细胞是autoHSCT后最早恢复的淋巴细胞亚群,在抗肿瘤免疫中发挥关键作用。本研究深入表征了不同血液系统恶性肿瘤成人患者的NK细胞。结果显示,autoHSCT后即刻,NK细胞会短暂获得类似蜕膜NK细胞的表型,呈现较不成熟且活化的状态,同时抑制性受体上调、活化受体下调。此类蜕膜样活化表型表现为CD56、CD9、CD49a、CD151、CD38和HLA-DR表达增加。研究者还检测了血浆细胞因子水平,并发现细胞因子浓度与NK细胞表型变化相关。体外实验提示,这些表型变化可能调节NK细胞功能。最后,在非霍奇金淋巴瘤(NHL)患者中,NK细胞成熟状态与无进展生存期相关。总体而言,本研究加深了对autoHSCT后免疫重建期间NK细胞动态变化的认识,并可能为改进患者管理提供信息。

展开英文摘要原文

Early immune reconstitution following autologous hematopoietic stem cell transplantation (autoHSCT) is associated with improved outcome in various cancers. Natural killer (NK) cells are the first lymphocyte subset to recover post-autoHSCT and play a crucial role in antitumor immunity. In this study, we have performed an in-depth characterization of NK cells in adult patients with different hematological malignancies. Our results revealed that, immediately after autoHSCT, NK cells transiently acquired a decidual-like phenotype, displayed a more immature and activated state, and exhibited an upregulation of inhibitory receptors and a downregulation of activating receptors. This decidual-like and activated phenotype was characterized by increased expression of CD56, CD9, CD49a, CD151, CD38 and HLA-DR. Additionally, we assessed plasma cytokine levels and identified associations between cytokine concentrations and NK cell phenotypic changes. In vitro experiments suggested that these phenotype alterations could modulate NK cell function. Finally, in patients with non-Hodgkin lymphoma (NHL), we observed a correlation between NK cell maturation status and progression-free survival. Collectively, our findings provide valuable insights into NK cell dynamics during immune reconstitution following autoHSCT and may inform of strategies for improving patients' management.

论文信息

作者
Astarloa-Pando G、Sandá V、Amarilla-Irusta A、Lopez-Pardo A、San Juan I、Iturbe-Larrondo A、Pérez-Garay R、Pérez-Fernández S
单位
Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.Spain
期刊
Frontiers in immunology2025
原文标识
PubMed 41126839 · DOI 10.3389/fimmu.2025.1629118